The Vanguard Group, Inc. recently announced the acquisition of new stake in TG Therapeutics Inc (NASDAQ:TGTX). The institutional investor has increased its shareholding in the Healthcare company by 0.07% to 13.06 million shares with purchase of 9159.0 shares. This fresh investment now brings its stake to 8.63% valued currently at $167.36 million. In addition, SSgA Funds Management, Inc. raised its holdings by 4.19 million to 9.82 million shares. And BlackRock Fund Advisors has lifted its position by 1.42% or 0.12 million shares – to 8.49 million shares.
With over 4.86 million TG Therapeutics Inc (TGTX) shares trading Tuesday and a closing price of $16.99 on the day, the dollar volume was approximately $82.65 million. The shares have shown a negative half year performance of -25.58% and its price on 12/26/23 lost nearly -0.06%. Currently, there are 146.39M common shares owned by the public and among those 137.41M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for TGTX have a consensus price objective of $27.81. The analysts have set the share’s price value over the next 12 months at a high of $41.00 and a low of $6.00. The average price target is 38.91% above its recent price level and a downside to the estimated low will see the stock lose -183.17% over that period. But an upside of 58.56% will see the stock hit the forecast high price target while median target price for the stock is $30.75.
Insiders at the company have transacted a total of 12 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 1,259,000 shares. Insider sales of the common stock occurred on 4 occasions, with total insider shares sold totaling 158,501 shares.
The top 3 mutual fund holders in TG Therapeutics Inc are SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund. SPDR S&P Biotech ETF owns 7.56 million shares of the company’s stock, all valued at over $96.78 million. The company bought an additional 35085.0 shares recently to bring their total holdings to about 4.99% of the shares outstanding. Vanguard Total Stock Market ETF bought 6064.0 shares to see its total holdings expand to 4.25 million shares valued at over $54.47 million and representing 2.81% of the shares outstanding. Vanguard Small Cap Index Fund bought 10792.0 shares to bring its total holdings to over 3.52 million shares at a value of $45.14 million. Vanguard Small Cap Index Fund now owns shares totaling to 2.33% of the shares outstanding.
Shares of TG Therapeutics Inc (NASDAQ: TGTX) opened at $17.21, up $0.21 from a prior closing price of $17.00. However, the script later moved the day high at 17.34, down -0.06%. The company’s stock has a 5-day price change of -6.60% and 93.73% over the past three months. TGTX shares are trading 43.62% year to date (YTD), with the 12-month market performance up to 98.02% higher. It has a 12-month low price of $6.46 and touched a high of $35.67 over the same period. TGTX has an average intraday trading volume of 5.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.26%, 42.75%, and 0.56% respectively.
Institutional ownership of TG Therapeutics Inc (NASDAQ: TGTX) shares accounts for 60.19% of the company’s 146.39M shares outstanding. Mutual fund holders own 27.62%, while other institutional holders and individual stakeholders account for 32.60% and 17.63% respectively.
It has a market capitalization of $2.57B and a beta (3y monthly) value of 2.32. The earnings-per-share (ttm) stands at -$0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.82% over the week and 6.43% over the month.
Analysts forecast that TG Therapeutics Inc (TGTX) will achieve an EPS of -$0.12 for the current quarter, -$0.09 for the next quarter and $0.01 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.2 while analysts give the company a high EPS estimate of -$0.04. Comparatively, EPS for the current quarter was -$0.39 a year ago. Earnings per share for the fiscal year are expected to increase by 96.50%, and 152.17% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate TG Therapeutics Inc (TGTX) as a “Strong Buy” at a consensus score of 1.56. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 1 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TGTX, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on August 02, 2023, with the firm’s price target at $16-$12.
